Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography

Academic Radiology

Volumn 20, Issue 1, 2013, Pages 25-31

  Hou, Zhi hui ^a   Lu, Bin ^a   Gao, Yang ^a   Cao, Hui li ^a   Yu, Fang fang ^a   Jing, Na ^a   Chen, Xi ^a   Cong, Xiang feng ^a   Roy, Sion K ^b   Budoff, Matthew J ^b  

^a FUWAI HOSPITAL   (China)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

64 slice CT; Matrix metalloproteinase 9; Myeloperoxidase; Nonobstructive plaque

Indexed keywords

CHOLESTEROL; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RIGHT CORONARY ARTERY; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IOHEXOL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEROXIDASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84870905184     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2012.07.014     Document Type: Article

References (26)

1. Matsumoto N., Sato Y., Yoda S., et al. Prognostic value of nonobstructive CT low-dense coronary artery plaques detected by multislice computed tomography. Circ J 2007, 71:1898-1903.
2. Min J.K., Lin F.Y., Dunning A.M., et al. Incremental prognostic significance of left ventricular dysfunction to coronary artery disease detection by 64-detector row coronary computed tomographic angiography for the prediction of all-cause mortality: results from a two centre study of 5330 patients. Eur Heart J 2010, 31:1212-1219.
3. Virmani R., Burke A.P., Farb A., et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47(suppl):C13-C18.
4. Ehara S., Kobayashi Y., Yoshiyama M., et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004, 110:3424-3429.
5. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
6. Newby A.C. Dual role of matrix metalloproteinases (matrixes) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
7. Brown D.L., Hibbs M.S., Kearney M., et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125-2131.
8. Arnhord J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 2004, 69:4-9.
9. Daugherty A., Dunn J.L., Rateri D.L., et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
10. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
11. Lin Fay Y., Shaw Leslee J., Dunning Allison M., et al. Mortality risk in symptomatic patients with nonobstructive coronary artery disease. J Am Coll Cardiol 2011, 58:510-519.
12. Cheng V.Y., Wolak A., Gutstein A., et al. Low-density lipoprotein and noncalcified coronary plaque composition in patients with newly diagnosed coronary artery disease on computed tomographic angiography. Am J Cardiol 2010, 105:761-766.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
14. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988, 12:56-62.
15. Corrales-Medina V.F., Madjid M., Musher D.M. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010, 10:83-92.
16. Muller J.E., Tawakol A., Kathiresan S., et al. New opportunities for identification and reduction of coronary risk: treatment of vulnerable patients, arteries, and plaques. J Am Coll Cardiol 2006, 47(suppl):C2-C6.
17. Luttun A., Lutgens E., Manderveld A., et al. Loss of matrix metalloproteinase-9 or matrixmetalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004, 109:1408-1414.
18. Loftus I.M., Naylor A.R., Goodall S., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000, 31:40-47.
19. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004, 24:1143-1146.
20. Sugiyama S., Okada Y., Sukhova G.K., et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating-factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158:879-891.
21. Fu X., Kassim S.Y., Parks W.C., et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001, 276:41279-41287.
22. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
23. Derosa G., D'Angelo A., Ciccarelli L., et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006, 13:227-231.
24. Tayebjee M.H., Nadar S., Blann A.D., et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo- Scandinavian Cardiac Outcomes Trial ASCOT. Am J Hypertens 2004, 17:764-769.
25. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004, 109:2850-2856.
26. Noji Y., Kajinami K., Kawashiri M.A., et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001, 39:380-384.